Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.
An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.
A JAMA Network Open study dives into how the utilization of a digital patient portal changed during the COVID-19 pandemic, while also exploring ways that multimorbidity and socioeconomic disparities affected those statistics.
With its aims to protect healthcare consumers against the dangers of counterfeit, contaminated, stolen or otherwise harmful drugs, the DSCSA represents a significant step forward in securing the pharmaceutical supply chain.
In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement & Policy Insights, Cencora, offers his thoughts on where the Inflation Reduction Act will be five to 10 years from now.
A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective.
In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement, Policy Insights, Cencora, provides a look at his recent webinar focused on the implications of the Inflation Reduction Act.
Compared with piperacillin/tazobactam, Exblifep (cefepime/enmetazobactam) showed noninferiority and superiority in a clinical cure and microbiological eradication of complicated urinary tract infections.
Epkinly (epcoritamab-bysp), a subcutaneously administered, T-cell engaging, bispecific antibody, was previously granted Breakthrough Therapy Designation for the treatment of patients with relapsed or refractory follicular lymphoma following two or more prior lines of therapy.
SKYTyphoid, a single-dose typhoid conjugate vaccine jointly developed by SK bioscience and the International Vaccine Institute, showed a positive immunogenicity and safety profile across age groups.
Trial data show Dupixent is the first and only novel biologic drug to significantly improve lung function and reduce severe acute exacerbations in adults with uncontrolled chronic obstructive pulmonary disease.
A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.